Evidence map›Paper›PMID 38982118›Full record

ArticleScientific reports2024

Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125.

Gatot Nyarumenteng Adhipurnawan Winarno, Ali Budi Harsono, Dodi Suardi, Siti Salima, Kemala Isnainiasih Mantilidewi, Hartanto Bayuaji, Ayu Insafi Mulyantari, Fajar Awalia Yulianto, Hadi Susiarno

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gatot Nyarumenteng Adhipurnawan WinarnoDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia. gatot.nyarumenteng@unpad.ac.id.ORCID 0000-0001-8537-5415
Ali Budi HarsonoDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.
Dodi SuardiDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.
Siti SalimaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.
Kemala Isnainiasih MantilidewiDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.
Hartanto BayuajiDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.
Ayu Insafi MulyantariDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.
Fajar Awalia YuliantoDepartment of Public Health, Medical Faculty, Universitas Islam Bandung, Bandung, Indonesia.
Hadi SusiarnoDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Prof Eykman Street No 38, Bandung, 40161, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global challenges in ovarian cancer underscore the need for cost-effective screening. This study aims to assess the role of pretreatment Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte-Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR), and CA-125 in distinguishing benign and malignant ovarian tumors, while also constructing nomogram models for distinguish benign and malignant ovarian tumor using inflammatory biomarkers and CA-125. This is a retrospective study of 206 ovarian tumor patients. We conducted bivariate analysis to compare mean values of CA-125, LMR, NLR, and PLR with histopathology results. Multiple regression logistic analysis was then employed to establish predictive models for malignancy. NLR, PLR, and CA-125 exhibited statistically higher levels in malignant ovarian tumors compared to benign ones (5.56 ± 4.8 vs. 2.9 ± 2.58, 278.12 ± 165.2 vs. 180.64 ± 89.95, 537.2 ± 1621.47 vs. 110.08 ± 393.05, respectively), while lower LMR was associated with malignant tumors compared to benign (3.2 ± 1.6 vs. 4.24 ± 1.78, p = 0.0001). Multiple logistic regression analysis revealed that both PLR and CA125 emerged as independent risk factors for malignancy in ovarian tumors (P(z) 0.03 and 0.01, respectively). Utilizing the outcomes of multiple regression logistic analysis, a nomogram was constructed to enhance malignancy prediction in ovarian tumors. In conclusion, our study emphasizes the significance of NLR, PLR, CA-125, and LMR in diagnosing ovarian tumors. PLR and CA-125 emerged as independent risk factors for distinguishing between benign and malignant tumors. The nomogram model offers a practical way to enhance diagnostic precision.

Indexed as

Biomarkers, TumorCA-125 AntigenNomogramsOvarian NeoplasmsAdultAgedBlood PlateletsFemaleHumansLymphocytesMiddle AgedNeutrophilsRetrospective StudiesBiomarkers, TumorCA-125 AntigenCA125Inflammatory biomarkerOvarian cancerOvarian tumors

Identifiers

PMID38982118
PMCPMC11233513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.